Quick Answer
Aldeyra Therapeutics, Inc. reported Net Income Loss of -$33.85 million for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +39.4% in Net Income Loss from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$3.97 million | Q2 2013: -$1.57 million | Q3 2013: $9.31 million | Q1 2014: $401.8 thousand | Q2 2014: -$1.14 million | Q3 2014: -$2.01 million | Q1 2015: -$2.14 million | Q2 2015: -$2.23 million | Q3 2015: -$3.37 million | Q1 2016: -$4.97 million | Q2 2016: -$4.30 million | Q3 2016: -$4.78 million | Q1 2017: -$5.09 million | Q2 2017: -$5.31 million | Q3 2017: -$4.99 million | Q1 2018: -$8.40 million | Q2 2018: -$9.05 million | Q3 2018: -$10.81 million | Q1 2019: -$15.62 million | Q2 2019: -$13.33 million | Q3 2019: -$18.72 million | Q1 2020: -$9.87 million | Q2 2020: -$7.52 million | Q3 2020: -$8.87 million | Q1 2021: -$11.29 million | Q2 2021: -$14.94 million | Q3 2021: -$15.79 million | Q1 2022: -$16.79 million | Q2 2022: -$17.78 million | Q3 2022: -$14.55 million | Q1 2023: -$15.62 million | Q2 2023: -$8.99 million | Q3 2023: -$8.19 million | Q1 2024: -$8.08 million | Q2 2024: -$16.85 million | Q3 2024: -$15.11 million | Q1 2025: -$9.93 million | Q2 2025: -$9.77 million | Q3 2025: -$7.69 million.
- Over the full 13 years of available data (2013 to 2025), Aldeyra Therapeutics, Inc.'s Net Income Loss has declined by 359.2%.
- Historical annual values: Fiscal year 2025: -$33.85 million | Fiscal year 2024: -$55.85 million | Fiscal year 2023: -$37.54 million | Fiscal year 2022: -$62.02 million | Fiscal year 2021: -$57.78 million | Fiscal year 2020: -$37.55 million | Fiscal year 2019: -$60.83 million | Fiscal year 2018: -$38.89 million | Fiscal year 2017: -$22.34 million | Fiscal year 2016: -$18.70 million | Fiscal year 2015: -$12.09 million | Fiscal year 2014: -$5.19 million | Fiscal year 2013: $13.06 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: